Women with breast cancer, who were also carriers of BRCA1 or BRCA2 mutations and after mastectomy, were received as part of their reconstruction surgery, the texture was received as part of the surgery, the possibility of developing a rare T-sail lymphoma, a rare T-sail lymphoma, was likely to develop a rare T-sail lymphoma. According to a study, according to. Blood progression.

Our findings suggest that BRCA1 and BRCA2 mutation are an important risk factor to develop this type of lymphoma, which confirm the earlier suggestions of a potential role. It is possible that lymphoma associated with transplantation is still another cancer that may cause them. genetic mutation,

Paola Gione, MD, lead researcher, lymphoma expert at Memorial Slone Catering Cancer Center (MSKCC)

She says that analysis underlines women’s need to include their personal history of mastectomy and long transplants after avoiding breast cancer.

This is the first major study to see if the BIA-ALCL phenomenon is more in women who have BRCA mutations, which is also responsible for the onset of breast cancer in 5–10% of cases. Moving a harmful mutation in the BRCA 1 or BRCA 2 gene increases the risk of many cancers, including the breast, ovary, pancreas, and skin.

Earlier studies showed a relationship between the texture implants and the development of the BIA-Alola, which missed them from the European and American markets in 2019. BIA-LCL is of one type Tea cell Lymphoma that is produced near the textured breast implants, either as a collection of fluid or mass. It usually develops after seven to 10 years when women have to undergo reconstruction surgery with mastectomy and transplantation.

In 2023, the US Food and Drug Administration (FDA) reported a total of 1,264 cases and 63 deaths related to BIA-ALCL. While textured breast implants were used in the US about 12% of reconstruction surgery, they were Go-Two in Europe, which were used in 95% of surgery. Breast implants usually change every 10 to 15 years, so there are many women who are still these transplants in their body, Dr. Gheon explained.

“If we see full numbers [seen in this study]This is still quite rare, but the important thing to note is that when we look at women with this genetic tendency, there is a big leap in the percentage with this lymphoma, “he said. Other factors, in which implant filling (saline or silicone), breast cancer surgery, and pre -cancer were associated with treatment.

In this study, Dr. Gione and his colleagues pulled out of the unique coast of more than 3,000 women of MSKCC, who had breast implants as part of their breast cancer treatment and have been followed with time to assess for complications. Within this group, 520 women were tested for BRCA genes. They compared the prevalence of BRCA1 or BRCA2 mutation, confirmed through testing, among women who did not develop BIA-ALCL after reconstruction with only textured implants; The smooth surface devices are not thought to carry forward the risk of lymphoma, Dr. Gheon explained.

The women were followed in the middle of 11.5 years. Among 520 women suffering from breast cancer tested for BRCA, 8.3%, or 43 patients were carriers of BRCA1 or BRCA2 mutations. The age-time rate of developing BIA-ALCl for women with BRCA1 or BRCA2 mutations was 16 times the rate of BIA-ALCL in women without genetic mutations. Researchers also conducted a case-control study with 13 BIA-ALCL cases, which matches one to three with 39 controls, showing that the frequency of BRCA1 or BRCA2 mutation in BIA-ALCL cases was much higher than the frequency controls of mutations.

“The implants that are now installed are theoretically safe; however, there are still a lot of women who are living with textured breast implants, so it is important that women know what they have transplants and talk with their doctor and remember to report this surgery as part of their medical history,” Breast cancer diagnosis at a young age.

Given the low risk of BIA-ALCL, the FDA is not advised to transplant until women have symptoms. Symptoms may include pain, lumps, swelling or unexpected changes in breast size. However, researchers said that the findings of the study should indicate women who have done surgery of reconstruction of breast cancer due to breast cancer, which they have about the type of breast transplantation to openly discuss with their health care team and what steps they can take to reduce any risk. This is especially true if his plastic surgeon suggests that it is time to change the transplant.

The study did not include women with BRCA1 or BRCA2 mutations, who performed a immunological surgery to prevent breast cancer.

Dr. Gione and Team will continue to follow these women, as well as the texture implants removed to others. This study is limited in the fact that it is from a single institute, although it involves a diverse population and a very long follow -up.

The study was funded by the National Institute of Health’s National Cancer Institute.